Back to News
Market Impact: 0.3
Enliven Gets FDA Alignment For Phase 3 Relcobatinib Trial In Blood Cancer
Source: Nasdaq
Healthcare & BiotechRegulation & LegislationCompany Fundamentals
Enliven Therapeutics reported alignment with the U.S. FDA on the final design of the ENABLE-2 trial of relcobatinib in adults with previously treated chronic myelo—; the article text is truncated before the condition is fully specified. The design agreement is a clinical-development milestone, but no trial results, timeline, or financial figures are provided.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.20
Ticker Sentiment
ELVN0.60
More News
- Why is SK Hynix stock gaining today?
- High Court coal decision, Firmus IPO, diesel prices
- Elon Musk blames Indian 'oligarchs' for stalling Starlink launch
- Former world No. 1 Jon Rahm's lawyer tells court Spaniard is done with LIV Golf after three seasons
- Anthropic will be 'most ridiculous IPO' of year, analyst says
- Levi Strauss hikes profit guidance after tariff refunds, but its sales outlook is less optimistic
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- Weekly Update: Adding Live MBO Level 3 Data - Liquidity Heatmap, OFI Charts, and More
- Alternative Data Due Diligence for Institutional Investors